Vaccines, new opportunities for a new society

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 34, 2014, Pages 12288-12293

  Rappuoli, Rino ^a   Pizza, Mariagrazia ^a   Del Giudice, Giuseppe ^a   De Gregorio, Ennio ^a  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

Adjuvants; Cost effectiveness; Immunotherapy; Life expectancy; Reverse vaccinology

Indexed keywords

VACCINE; CANCER VACCINE;

AGE DISTRIBUTION; CANCER PREVENTION; CANCER THERAPY; CHILDHOOD DISEASE; COMMUNICABLE DISEASE; COST EFFECTIVENESS ANALYSIS; DEATH; DEGENERATIVE DISEASE; GROUPS BY AGE; HEALTH ECONOMICS; HUMAN; IMMUNE SYSTEM; INFECTION; INFECTION CONTROL; INFECTION PREVENTION; LIFE EXPECTANCY; MEDICAL HISTORY; MEDICAL SOCIETY; MEDICAL TECHNOLOGY; NON COMMUNICABLE DISEASE; PRIORITY JOURNAL; REVIEW; VACCINATION; WORLD HEALTH ORGANIZATION; COMMUNICABLE DISEASE CONTROL; COMMUNICABLE DISEASES, EMERGING; COST BENEFIT ANALYSIS; ECONOMICS; ISOLATION AND PURIFICATION; NEOPLASMS; NEURODEGENERATIVE DISEASES; POVERTY; PROCEDURES; SOCIAL STATUS; SYNTHETIC BIOLOGY; TRENDS;

CANCER VACCINES; COMMUNICABLE DISEASE CONTROL; COMMUNICABLE DISEASES, EMERGING; COST-BENEFIT ANALYSIS; HUMANS; LIFE EXPECTANCY; NEOPLASMS; NEURODEGENERATIVE DISEASES; POVERTY; SOCIAL CONDITIONS; SYNTHETIC BIOLOGY; VACCINATION; VACCINES;

EID: 84906658966     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1402981111     Document Type: Review

References (63)

1. Arias E (2012) United States life tables, 2008. Natl Vital Stat Rep 61(3):1-64.
2. van Panhuis WG, et al. (2013) Contagious diseases in the United States from 1888 to the present. N Engl J Med 369(22):2152-2158.
3. Murphy SL, et al. (2013) Deaths. Final data for 2010. Natl Vital Stat Rep 61(4):1-118.
4. Oldstone MBA (1978) Viruses, Plagues, and History (Oxford Univ Press, Oxford).
5. Wang H, et al. (2012) Age-specific and sex-specific mortality in 187 countries, 1970-2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 380(9859):2071-2094.
6. Keja K, Chan C, Hayden G, Henderson RH (1988) Expanded programme on immunization. World Health Statistics Quarterly. Rapport rimestriel de statistiques sanitaires mondiales 41(2):59-63.
7. World Health Organization (2013) Global Vaccine Action Plan 2011 - 2020. Available at www.who.int/immunization/global-vaccine-action-plan/GVAP-doc-2011- 020/en/index.html. Accessed June 1, 2014.
8. Lozano R, et al. (2012) Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 380(9859):2095-2128.
9. Jamison DT, et al. (2013) Global health 2035: A world converging within a generation. Lancet 382(9908):1898-1955.
10. Anonymous (2014) Grand convergence: A future sustainable development goal? Lancet 383(9913):187.
11. Thucydides (1989) History of the Peloponnesian War (Univ of Chicago Press, Chicago).
12. Jenner E (1798) An Inquiry into the Causes and Effects of the Variolae Vaccinae (Sampson Low, London).
13. Tognotti E (2010) The eradication of smallpox, a success story for modern medicine and public health: what lessons for the future? J Infect Dev Ctries 4(5):264-266.
14. Pasteur L (1880) De l'attenuation du virus du cholera des poules. C R Acad Sci Paris 91:673-680. French.
15. Pasteur L (1885) Méthode pour prévenir la rage après morsure. C R Acad Sci Paris 101:765-772. French.
16. Plotkin SA, Plotkin SL (2011) The development of vaccines: How the past led to the future. Nat Rev Microbiol 9(12):889-893.
17. Plotkin S (2014) History of vaccination. Proc Natl Acad Sci USA 111:12283-12287.
18. Valenzuela P, Medina A, Rutter WJ, Ammerer G, Hall BD (1982) Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature 298(5872):347-350. (Pubitemid 12044287)
19. Zhou J, Sun XY, Stenzel DJ, Frazer IH (1991) Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 185(1):251-257.
20. Pizza M, et al. (1989) Mutants of pertussis toxin suitable for vaccine development. Science 246(4929):497-500. (Pubitemid 19273940)
21. Rappuoli R (1997) Rational design of vaccines. Nat Med 3(4):374-376.
22. Schneerson R, et al. (1980) Haemophilus influenzae type B polysaccharide-protein conjugates: Model for a new generation of capsular polysaccharide vaccines. Prog Clin Biol Res 47:77-94.
23. Pizza M, et al. (2000) Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 287(5459):1816-1820.
24. Sette A, Rappuoli R (2010) Reverse vaccinology: Developing vaccines in the era of genomics. Immunity 33(4):530-541.
25. Dormitzer PR, Ulmer JB, Rappuoli R (2008) Structure-based antigen design: A strategy for next generation vaccines. Trends Biotechnol 26(12):659-667.
26. McLellan JS, et al. (2013) Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 342(6158):592-598.
27. Correia BE, et al. (2014) Proof of principle for epitope-focused vaccine design. Nature 507(7491):201-206.
28. Dormitzer PR, et al. (2013) Synthetic generation of influenza vaccine viruses for rapid response to pandemics. Sci Trans Med 5(185):185ra168.
29. Hekele A (2013) Rapidly produced SAM® vaccine against H7N9 influenza is immunogenic in mice. Emerg Microb Infect 2:e52.
30. Ladjemi MZ (2012) Anti-idiotypic antibodies as cancer vaccines: Achievements and future improvements. Front Oncol 2:158.
31. Ulmer JB, et al. (1993) Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259(5102):1745-1749. (Pubitemid 23114660)
32. Mannino S, et al. (2012) Effectiveness of adjuvanted influenza vaccination in elderly subjects in northern Italy. Am J Epidemiol 176(6):527-533.
33. Vesikari T, et al. (2011) Oil-in-water emulsion adjuvant with influenza vaccine in young children. N Engl J Med 365(15):1406-1416.
34. Mbow ML, De Gregorio E, Valiante NM, Rappuoli R (2010) New adjuvants for human vaccines. Curr Opin Immunol 22(3):411-416.
35. Maisonneuve C, Bertholet S, Philpott DJ, De Gregorio E (2014) Unleashing the potential of NOD- and Toll-like agonists as vaccine adjuvants. Proc Natl Acad Sci USA 111:12294-12299.
36. Bejon P, et al. (2008) Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med 359(24):2521-2532.
37. Barouch DH, et al. (2013) Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 503(7475):224-228.
38. Grupp SA, et al. (2013) Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368(16):1509-1518.
39. Porter DL, Levine BL, Kalos M, Bagg A, June CH (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365(8):725-733.
40. Wolchok JD, et al. (2013) Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369(2):122-133.
41. von Behring E, et al. (1890) Uber das Zustandekommen der Diphtherie-Immunitat und der Tetanus-Immunitat bie Tieren. Dtsch Med Wochenschr 16:1113-1114. German.
42. von Behring E (1890) Uber das Zustandekommen der Diphtherie-Immunitat und der Tetanus-Immunitat bie Tieren. Dtsch Med Wochenschr 16:1145-1148. German.
43. Rappuoli R, Aderem A (2011) A 2020 vision for vaccines against HIV, tuberculosis and malaria. Nature 473(7348):463-469.
44. Rappuoli R, Mandl CW, Black S, De Gregorio E (2011) Vaccines for the twenty-first century society. Nat Rev Immunol 11(12):865-872.
45. World Health Organization (2012) Meeting of the Strategic Advisory Group of Experts on immunization, April 2012 - conclusions and recommendations. Wkly Epidemiol Rec 87(21):201-216.
46. Rappuoli R, Black S (2013) Introduction: Addressing the challenge of group B streptococcal disease. Vaccine 31(Suppl 4):D1-D2.
47. Morens DM, Folkers GK, Fauci AS (2004) The challenge of emerging and re-emerging infectious diseases. Nature 430(6996):242-249. (Pubitemid 38902437)
48. Acuna-Soto R, Stahle DW, Cleaveland MK, Therrell MD (2002) Megadrought and megadeath in 16th century Mexico. Emerg Infect Dis 8(4):360-362. (Pubitemid 34415196)
49. Morens DM, Fauci AS (2013) Emerging infectious diseases: Threats to human health and global stability. PLoS Pathog 9(7):e1003467.
50. Kane MA (2012) Preventing cancer with vaccines: Progress in the global control of cancer. Cancer Prev Res (Phila) 5(1):24-29.
51. Lollini PL, Cavallo F, Nanni P, Forni G (2006) Vaccines for tumour prevention. Nat Rev Cancer 6(3):204-216. (Pubitemid 43292564)
52. Naz RK, Shiley B (2012) Prophylactic vaccines for prevention of prostate cancer. Front Biosci (Schol Ed) 4:932-940.
53. Michael A, Relph K, Annels N, Pandha H (2013) Prostate cancer vaccines. Expert Rev Vaccines 12(3):253-262.
54. Panza F, et al. (2012) Immunotherapy for Alzheimer's disease: From anti-β-amyloid to tau-based immunization strategies. Immunotherapy 4(2):213-238.
55. Lambracht-Washington D, Rosenberg RN (2013) Advances in the development of vaccines for Alzheimer's disease. Discov Med 15(84):319-326.
56. MacLennan S (2014) Vaccines against poverty. Proc Natl Acad Sci USA 111:12307-12312.
57. Blower S, Bernoulli D (2004) An attempt at a new analysis of the mortality caused by smallpox and of the advantages of inoculation to prevent it. 1766. Rev Med Virol 14(5):275-288.
58. Black S (2013) The role of health economic analyses in vaccine decision making. Vaccine 31(51):6046-6049.
59. Mekalanos JJ (2013) Vaccine economics: What price has human life? Sci Transl Med 5(204):204ed16.
60. Institute of Medicine of the National Academies (2012) Ranking Vaccines: A Prioritization Framework - Phase I: Demonstration of Concept and a Software Blueprint. Available at www.nap.edu/smartvaccines. Accessed June 1, 2014.
61. Institute of Medicine of the National Academies (2013) Ranking Vaccines: A Prioritization Software Tool - Phase II: Prototype of a Decision-Support System. Available at www.nap.edu/smartvaccines. Accessed June 1, 2014.
62. Phelps C, et al. (2014) A priority-setting aid for new vaccine candidates. Proc Natl Acad Sci USA 111(9):3199-3200.
63. Bärnighausen T, Bloom DE, Cafiero-Fonseca ET, O'Brien JC (2014) Valuing vaccination. Proc Natl Acad Sci USA 111:12313-12319.